GlycoMimetics, Inc. (GLYC)
$1.72
Rating:
Recommendation:
Buy
| Symbol | GLYC |
|---|---|
| Price | $1.72 |
| Beta | 2.059 |
| Volume Avg. | 0.12M |
| Market Cap | 110.756M |
| Shares () | - |
| 52 Week Range | 1.11-4.16 |
| 1y Target Est | - |
| DCF Unlevered | GLYC DCF -> | |
|---|---|---|
| DCF Levered | GLYC LDCF -> | |
| ROE | -109.37% | Strong Sell |
| ROA | -106.11% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 2173.56% | Strong Buy |
| P/E | -2.73 | Sell |
| P/B | 2.38 | Strong Buy |
Latest GLYC news
About
Download (Excel)GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.